Beactica Therapeutics Receives FDA Orphan Drug Designation for BEA-17 for the Treatment of Glioblastoma

UPPSALA, Sweden, Feb. 1, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BEA-17 for the treatment of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials